$680 Million is the total value of VR Adviser, LLC's 25 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 86.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CNST | CONSTELLATION PHARMACEUTICAL | $115,686,000 | +42.2% | 4,016,873 | 0.0% | 17.01% | +6.8% | |
| OLMA | New | OLEMA PHARMACEUTICALS INC | $73,860,000 | – | 1,536,193 | +100.0% | 10.86% | – |
| Sell | TRILLIUM THERAPEUTICS INC | $59,428,000 | -42.0% | 4,040,000 | -43.9% | 8.74% | -56.4% | |
| KNTE | New | KINNATE BIOPHARMA INC | $58,596,000 | – | 1,473,014 | +100.0% | 8.62% | – |
| ATHA | Buy | ATHIRA PHARMA INC | $57,938,000 | +106.3% | 1,691,623 | +11.2% | 8.52% | +55.0% |
| ALT | ALTIMMUNE INC | $50,760,000 | -14.5% | 4,500,000 | 0.0% | 7.46% | -35.8% | |
| KROS | KEROS THERAPEUTICS INC | $47,424,000 | +82.9% | 672,306 | 0.0% | 6.97% | +37.5% | |
| New | MARINUS PHARMACEUTICALS INC | $31,585,000 | – | 2,588,941 | +100.0% | 4.64% | – | |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $24,803,000 | +168.6% | 1,115,255 | +78.2% | 3.65% | +101.8% |
| RLMD | RELMADA THERAPEUTICS INC | $21,437,000 | -14.8% | 668,440 | 0.0% | 3.15% | -35.9% | |
| KURA | KURA ONCOLOGY INC | $18,780,000 | +6.6% | 575,000 | 0.0% | 2.76% | -19.9% | |
| VTGN | New | VISTAGEN THERAPEUTICS INC | $18,158,000 | – | 9,360,000 | +100.0% | 2.67% | – |
| CLDX | CELLDEX THERAPEUTICS INC | $14,016,000 | +18.1% | 800,000 | 0.0% | 2.06% | -11.2% | |
| SURF | Sell | SURFACE ONCOLOGY INC | $13,332,000 | -50.2% | 1,442,895 | -62.8% | 1.96% | -62.6% |
| ACRS | New | ACLARIS THERAPEUTICS INC | $12,648,000 | – | 1,954,932 | +100.0% | 1.86% | – |
| COGT | New | COGENT BIOSCIENCES INC | $12,227,000 | – | 1,088,817 | +100.0% | 1.80% | – |
| ALGS | New | ALIGOS THERAPEUTICS INC | $11,196,000 | – | 404,906 | +100.0% | 1.65% | – |
| GRTX | Buy | GALERA THERAPEUTICS INC | $9,390,000 | +1910.7% | 917,860 | +1677.0% | 1.38% | +1417.6% |
| SBTX | New | SILVERBACK THERAPEUTICS INC | $6,951,000 | – | 150,000 | +100.0% | 1.02% | – |
| BCTG | BCTG ACQUISITION CORP | $5,720,000 | +10.4% | 500,000 | 0.0% | 0.84% | -17.0% | |
| MTCR | Sell | METACRINE INC | $5,452,000 | -53.3% | 693,673 | -39.3% | 0.80% | -64.9% |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $4,170,000 | – | 245,122 | +100.0% | 0.61% | – |
| BCAB | New | BIOATLA INC | $3,401,000 | – | 100,000 | +100.0% | 0.50% | – |
| TSHA | TAYSHA GENE THERAPIES INC | $2,866,000 | +10.3% | 107,982 | 0.0% | 0.42% | -17.1% | |
| VRDN | New | VIRIDIAN THERAPEUTICS INC | $321,000 | – | 19,495 | +100.0% | 0.05% | – |
| MDNA | Exit | MEDICENNA THERAPEUTICS CORP | $0 | – | -92,453 | -100.0% | -0.08% | – |
| FSDC | Exit | FS DEVELOPMENT CORP-A | $0 | – | -500,000 | -100.0% | -1.10% | – |
| UMRX | Exit | UNUM THERAPEUTICS INC | $0 | – | -4,355,273 | -100.0% | -1.99% | – |
| ALXO | Exit | ALX ONCOLOGY HOLDINGS INC | $0 | – | -300,000 | -100.0% | -2.22% | – |
| MRNS | Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -1,192,883 | -100.0% | -3.00% | – |
| IMV | Exit | IMV INC | $0 | – | -4,000,000 | -100.0% | -3.47% | – |
| CRDF | Exit | CARDIFF ONCOLOGY INC | $0 | – | -1,271,985 | -100.0% | -3.53% | – |
| HGEN | Exit | HUMANIGEN INC | $0 | – | -2,332,516 | -100.0% | -4.86% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 12 | Q3 2023 | 12.7% |
| VIRIDIAN THERAPEUTICS INC | 12 | Q3 2023 | 13.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.3% |
| RELMADA THERAPEUTICS INC | 11 | Q3 2022 | 9.9% |
| GH RESEARCH PLC | 10 | Q3 2023 | 6.7% |
| ALTIMMUNE INC | 9 | Q3 2022 | 11.6% |
| MARINUS PHARMACEUTICALS INC | 9 | Q4 2022 | 5.7% |
| CELLDEX THERAPEUTICS INC | 9 | Q3 2022 | 7.6% |
| AFFIMED N V | 8 | Q3 2023 | 1.1% |
| INSTIL BIO INC | 7 | Q3 2022 | 18.7% |
View VR Adviser, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View VR Adviser, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.